



CLINICAL GUIDELINE

Combined Hormonal Contraception (CHC)

A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments.

Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty.

If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient.

Version Number:	1
Does this version include changes to clinical advice:	N/A
Date Approved:	2 nd December 2025
Date of Next Review:	31 st December 2027
Lead Author:	Kay McAllister
Approval Group:	Sandyford Governance Group
Guideline ID number:	1262

Important Note:

The online version of this document is the only version that is maintained. Any printed copies should therefore be viewed as 'Uncontrolled' and as such, may not necessarily contain the latest updates and amendments.

COMBINED HORMONAL CONTRACEPTION

What's New

- Include routine enquiry about over the counter medication including GLP1 agonists. Tirzepatide (known as Mounjaro) may reduce efficacy of ORAL contraception.
- It is possible that contraceptive effectiveness of combined hormonal contraception could be reduced during use of lamotrigine.

Combined Oral Contraception (COC)

- Described as any oral hormonal preparation containing an oestrogen in conjunction with a progestogen.
- In current practice, COCs contain 20 – 35 micrograms (mcg) of ethinylestradiol (EE) in combination with a progestogen.
- Progestogens include Norethisterone, Levonorgestrel, Desogestrel, Gestodene, Norgestimate and Drospirenone.
- The primary mode of action of this method is to prevent ovulation. These pills are packed in 21 day packs but are also available as every-day packs with placebo tablets to aid concordance with the method.
- Extended and tailored regimens can be offered (with the client made aware of off license use).
- There are 3 products containing oestradiol (however do not have SMC approval):
 - **Zoely®** oestradiol hemihydrate combined with nomegestrol in a 28 day pack
 - **Qlaira®** oestradiol valerate combined with dienogest in a 26/2 pack
 - **Droveils®** Estetrol combined with Drospirenone 24/4 pack

Combined Transdermal Patch (CTP)

- Currently in the UK there is one transdermal contraceptive patch which releases 33.9 micrograms Ethinylestradiol and 203 micrograms Norelgestromin per 24 hours (Evra®).
- One patch to be applied once weekly for three weeks, followed by a 7 day patch free interval.
- Extended regimens can also be discussed.

Combined Vaginal Ring (CVR)

- The combined vaginal ring (NuvaRing®NuvaRing®® or Syreniring®) consists of ethylene vinylacetate (latex-free) and releases 15 micrograms ethinylestradiol and 120 micrograms Etonogestrel daily. One ring should be inserted vaginally for 3 weeks of use per cycle.
- This should then be removed and a new ring inserted after a 7-day ring-free break. Extended and tailored regimens can also be discussed.

- **NuvaRing®NuvaRing®** must be kept refrigerated prior to dispensing to the client.
 - After removal from the fridge, NuvaRing® can be stored at room temperature and used within 4 months.
Therefore only supply 3 NuvaRing® at a time.
- **Syreniring®** does not require refrigeration.
 - 1 year supply can be dispensed at a time.
NuvaRing®NuvaRing®NuvaRing®NuvaRing®

Indications for CHC Use

- Those wishing to control their fertility or menstrual cycle and who have no contraindications to its use (see [UK Medical Eligibility Criteria](#))
- There is currently no evidence regarding risks associated with vaping, however CoSRH advise categorising as a smoker.
- Those wishing to use CHC for menstrual control should be informed that this is outside the product licence (with the exception of Qlaira).

Efficacy

- A Cochrane review comparing the combined patch, ring and pill has concluded that these methods have similar efficacy:
 - Perfect use: (following directions for use) the failure rate is 0.3%.
 - Typical use: (actual use including inconsistent or incorrect use) is 9%.
- **Inform users of the typical use failure rate.**

The CoSRH have recommended caution in women whose weight is greater than 90kg using the CTP, due to concerns over efficacy. This is independent of BMI. Alternatives should be considered.

Side Effects

Common side effects:

- Nausea
- Headache
- Mastalgia
- Skin reactions including photosensitivity
- Chloasma
- Reduced menstrual loss
- Unscheduled bleeding
- Amenorrhoea
- Contact lenses may irritate

Reassure there is no evidence suggesting an association between CHC and weight gain.

Less common side effects:

- Changes in libido
- Mood changes (no evidence causes depression)
- Chorea
- Hypertension
- Impairment of LFTs
- Hepatic tumours

Further information is available in the CoSRH guidance comparing the side effects of the [combined hormonal methods](#).

Risks

At first prescription of CHC all women should be informed that:

- CHC use is safe for the majority but can be associated with rare but serious harms;
- Venous thrombo-embolism (VTE):
 - There is a small increase in the risk of VTE with CHC use.
 - This risk is highest in the first 4 months of CHC use.
 - It reduces but remains stable thereafter.
 - The risk returns to that of non-users within weeks of discontinuation. (see table below).
 - When counselling it is important to emphasise that while some progestogens within CHCs may be associated with a higher risk of VTE than others, the risk of a venous thrombosis CHC users is very small – smaller than that associated with pregnancy and the puerperium.

CHC use and Risk of VTE

	Risk of VTE per 10,000 women years
Non contraceptive users and not pregnant	2
CHC containing ethinylestradiol plus levonorgestel, norgestimate or norethisterone	5-7
CHC containing etonogestrel (ring) or norelgestromin (patch)	6-12
CHC containing ethinylestradiol plus gestodene, desogestrel, drospirenone or cyproterone	9-12
Pregnancy	29
Immediate Postpartum period	300-400

- There may be a small increase in the risk of heart attack with CHC use. (Please see UKMEC tables)
- There may be an increased stroke risk, particularly in migraine sufferers with associated aura (see UKMEC)
- There is likely to be a small increase in breast cancer risk (RR 1.19 to 1.24) which returns to no increased risk 10 years after stopping CHC. Users of CHCs have not been found to be associated with increased mortality from breast cancer.
- There may be a very small increase in the risk of cervical cancer that increases with increasing duration of use. This returns to that of never-users 10 years after stopping CHC. There is no evidence of any increased cervical cancer risk when CHC is used for less than 5 years
- Use of CHC is associated with a reduced risk of ovarian and endometrial cancer that continues for several decades after stopping.

Reasons to Stop Immediately and Seek Medical Advice**Key symptoms that should prompt women to seek urgent medical review:**

- Calf pain, swelling and/or redness
- Chest pain and/or breathlessness and/or coughing up blood
- Loss of motor or sensory function

Key symptoms that should prompt women to seek medical review:

- Breast lump, unilateral nipple discharge, new nipple inversion, change in breast skin
- New onset migraine
- New onset sensory or motor symptoms in the hour preceding onset of migraine
- Persistent unscheduled vaginal bleeding

New medical diagnoses that should prompt women to seek advice from their contraceptive provider (and review of the suitability of CHC):

- High blood pressure
- High body mass index (>35 kg/m²)
- Migraine or migraine with aura
- Deep vein thrombosis or pulmonary embolism
- Blood clotting abnormality
- Antiphospholipid antibodies
- Angina, heart attack, stroke or peripheral vascular disease
- Atrial fibrillation
- Cardiomyopathy
- Breast cancer or breast cancer gene mutation
- Liver tumour
- Symptomatic gallstones

Possible Drug Interactions

It is recommended that you check the current status of drug interaction of new preparations with

[Medscape Drug Interaction Checker](#)., current CEU guidance, [BNF](#) and, if necessary, any interaction with [HIV drugs](#)

Ulipristal acetate (ellaOne®)

CoSRH CEU guidance on Emergency Contraception (EC)¹ has been updated to include more detailed advice on delaying versus immediate starting combined oral contraception (COC) after ulipristal acetate (UPA) EC use³.

If UPA-EC is chosen, hormonal contraception should not generally be started for 5 days after the UPA-EC has been taken.

There is one exception to this. In the specific situation in which combined oral contraceptive pills are restarted after a scheduled hormone-free interval and then pills are missed later in the first week of pill taking, use of LNG-EC should be considered but if UPA-EC is chosen, pill-taking can be resumed immediately.

Liver enzyme inducing drugs

- Increase the metabolism of estradiol and progestogens and the efficacy of CHC may be reduced.
- Risks of CHC use and taking liver enzyme inducing drugs outweigh potential benefits (UKMEC Category 3), and an alternative method unaffected by enzyme-inducing drugs is recommended.
- **Short term (< 2months) liver enzyme inducing drug use:**
Can continue using CHC but they should be advised to use additional contraceptive precautions (e.g. condoms) whilst taking the enzyme-inducing drug and for 28 days after stopping treatment.
To minimise the risk of contraceptive failure the CEU recommends an extended regimen (taking CHC continuously or tricycling with a shortened pill-/patch- or ring-free interval of 4 days).
- **Long term liver enzyme inducing drug use:**
If still chooses to use COC as a long-term method, she should use a regime containing at least 50 micrograms of ethinylestradiol.
A 50 micrograms EE dose may be made up from an appropriate 30 micrograms plus 20 micrograms preparation.
An extended or tricycling regime with a pill-free interval of 4 days should be followed. Additional contraception is not required.
If women are on Rifampicin or Rifabutin, an alternative method of contraception should be advised as the regimen above may not be effective.
- **Breakthrough bleeding:**
This may indicate low serum EE concentrations. If other causes (e.g. chlamydia) have been excluded, the dose of EE can be increased up to a maximum of 70 micrograms EE.

For women using the combined contraceptive patch or ring, information should be given on the use of alternative contraceptive methods if liver enzyme-inducers are to be used long term. The use of two patches or two rings is not recommended.

Lamotrigine:

It is possible that contraceptive effectiveness of combined hormonal contraception could be reduced during use of lamotrigine.

Oestrogen in CHC can reduce lamotrigine levels which may result in change in seizure frequency. Therefore women on lamotrigine should not start CHC without informing their neurologist.

Withdrawal of CHC in a client already on lamotrigine can result in lamotrigine toxicity, and patients should be made aware of this.

Further information is available in the summary of product characteristics (SPC) for lamotrigine: <http://www.medicines.org.uk/emc/>. It would be advisable to consider other methods.

Antibiotics

- Non-enzyme inducing antibiotics:
The CEU no longer advises that additional precautions are required to maintain contraceptive efficacy when using antibiotics with combined hormonal methods.
However if the antibiotics (and/or the illness) caused **vomiting or diarrhoea**, then the usual **additional precautions** relating to these conditions should be observed.
- Rifampicin:
If using Rifampicin short term (.e.g. for meningococcal meningitis prophylaxis) COC users should be advised to use a barrier method in addition to COC during treatment and for 28 days after stopping Rifampicin.

Anti-obesity medication

- [GLP1 agonists](#)

This depends on the type of GLP-1 agonist that you are using. Tirzepatide users should use a barrier method of contraception (e.g. condoms) in addition to COC for four weeks after starting the medication, and for four weeks after any increase in dose.

This is because tirzepatide works slightly differently to the other GLP-1 agonists. Alternatively consider another (non-oral) method of contraception

whilst using tirzepatide. There is currently no evidence that semaglutide, exenatide, liraglutide, dulaglutide or lixisenatide reduce the effectiveness of oral contraception (i.e. the combined pill, or the progestogen only pill/ “mini-pill”).

Diarrhoea and vomiting are common side effects of the GLP-1 agonists and can reduce the effectiveness of the pill. If vomiting occurs within three hours of taking the contraceptive pill, or severe diarrhoea occurs for more than 24 hours, missed pill guidance should be followed. You should consider an alternative non-oral method of contraception or the addition of condoms if diarrhoea or vomiting persists.

- Orlistat (Xenical/Alli) – these may cause diarrhoea and reduce absorption. Additional precautions are advised in these situations.

Further information regarding the effects of combined hormonal contraception on other medications can be found [CoSRH Drug interactions](#) guidance -

Assessment of Client Suitability

History:

Clinical history taking and examination allow an assessment of medical eligibility for CHC use and possible contraceptive options. In this context the history should include relevant social, sexual (to assess risk of sexually transmitted infections (STI's)), medical, family and drug history as well as details of reproductive health and previous contraceptive use.

This history should be updated annually.

Examination:

- Blood pressure and BMI should be recorded and noted
- Self-reported recordings are acceptable for remote prescribing
- Breast examination, pelvic and genital examinations, cervical cytology screening and routine lab tests do not contribute substantially to CHC safety and are not recommended routinely but should be performed if clinically indicated for other reasons

Choice of Preparation

First Line Choice: Levest
Second Line Choice: Rigevidon

Aim to choose the lowest dosage of oestrogen and progestogen that

- Maintains efficacy
- Has fewest side effects

- Gives good cycle control
- Takes into account differential risk of VTE
- Is cost effective

A monophasic COC containing 20 - 30 micrograms of ethinylestradiol with norethisterone or levonorgestrel is recommended as first line option. Examples are Rigevidon, Ovranelle and Microgynon 30,. Tailored regimens may improve bleeding patterns and hence improve compliance. Please see appendix for alternative CHC regimens and key messages for women considering tailored regimens.

Transdermal or intravaginal preparations may be advantageous in situations where GI absorption is compromised e.g. inflammatory bowel disease, or in situations where this method will improve compliance.

GGC Formulary link: [GGC Medicines - NHSGGC Adult Formulary](#)

Table: CHC Preparations

Monophasic preparations Grouped by progestogen type and generation	Oestrogen dose	Brand names
Norethisterone (1 st)	35 micrograms EE	Brevinor® Norimin®
Levonorgestrel (2 nd)	30 micrograms EE	Microgynon 30® Leandra® Ovranelle® Rigevidon® Levest® Ambelina
Desogestrel (3 rd)	30 micrograms EE	Marvelon® Gedarel 30/150® Cimizt®
	20 micrograms EE	Mercilon® Gedarel 20/150® Bimizza®
Gestodene (3 rd)	30 micrograms EE	Femodene® Katya® Millinette 30/75® Akizza
	20 micrograms EE	Femodette® Sunya® Millinette 20/75®
Cyproterone (equivalent to 3 rd)	35 micrograms EE	Co-cyprindiol Dianette® Clairette®, Teragezza
Norgestimate (equivalent to 2 nd)	35 micrograms EE	Cilique® Lizinna®

Drospirenone (4 th)	20 micrograms EE 30 micrograms EE	Eloine® Daylette® Yasmin® Lucette® Yacella® Dretine® Yiznell
Triphasic pills with varied progestogens	30 – 40 micrograms EE	TriRegol® Triadene
Phasic with Dienogest (4 th)	1 – 3 mg Estradiol valerate	Qlaira®
Nomegestrel acetate (4 th)	1.5mg Estradiol hemihydrate	Zoely®
Drospirenone (DRSP) 3mg	Estetrol E4 14.2mg	Droveils
Low Dose Patch with norelgestromin	20 micrograms EE	Evra®
Intravaginal ring with etonogestrel	15 micrograms EE	NuvaRing® SyreniRing®

Documentation

- The full visit history should be completed / updated on NaSH.
- Written method information or SMS leaflet including information about actions after missed pills, ring or patch and a contact number is given to client.
- Record prescription on NaSH.
- Nurse supplying where appropriate under patient group direction.

First Prescription

At first prescription of CHC all users should be informed that CHC is safe for the majority but can be associated with rare but serious harms. The risks, benefits and side effects mentioned above should be discussed.

Follow Up Arrangements

Return Visit:

- Encourage to attend their GP for follow-up and ongoing supply of combined hormonal contraception.
- 12 months' supply (except for NuvaRing®NuvaRing®) may be issued to clients at the initial visit and thereafter provided no problems have been identified.
- NuvaRing®NuvaRing® must be used within 4 months after dispensing. Clients should therefore only be issued with a 3-month supply at any visit. Even with extended use, no more than one box of 3 rings can be issued at one time.
- Consider notifying GP of prescription, if permission is given for correspondence.

Start Times:

Circumstances for CHC start	When to start	Additional contraceptive precautions required
Having menstrual cycles	Start CHC up to and including day 5 (day 1 for Qlaira®)	None
	At any other time if it is reasonably certain that is not pregnant (see Quick start protocol)	For 7 days 9 days for Qlaira®
Secondary amenorrhoea	At any time, if it is reasonably certain that is not pregnant	For 7 days 9 days for Qlaira®
Postpartum, not breastfeeding	Start CHC on day 21 postpartum if vaginal delivery and no additional risk factors for VTE = UKMEC 2 (UKMEC 3 if other VTE risk factors)	None
	If >21 days postpartum and cycles have returned as for others having menstrual cycles	None if Day 1-5 For 7 days if started out-with days 1-5
	If >21 days postpartum and cycles have not returned as for others with amenorrhoea	For 7 days 9 days for Qlaira®
Postpartum, breastfeeding	Please refer to UKMEC for CHC use under different circumstances	
Post Abortion	Up to and including day 5 post medical or surgical abortion <24 weeks gestation (day 1 for Qlaira®)	None

Switching from other contraceptive methods:		
All Hormonal methods except LNG-IUD: *	CHC can be started immediately if hormonal method used consistently and correctly, or if it is reasonably certain is not pregnant. If previous method injectable or implant can start CHC at any time up to when repeat injection due or implant removed (not expired)	None if previous method reliably suppresses ovulation If POP (other than Cerelle®) for 7 days (9 days if Qlaira®)
Switching from IUS	CHC can be started immediately Removal of LNG-IUD is not recommended if unprotected intercourse has occurred in the last 7 days due to risk of pregnancy	For 7 days (9 days for Qlaira®) Or defer removal of LNG-IUD until new method effective
Switching from IUD	CHC can be started at any time of the cycle	None if up to and including day 5 (IUD can be removed at that time)

		If starting CHC after day 5, required for 7 days (9 days for Qlaira®) and defer removal of IUD if unprotected intercourse in the previous 7 days
Switching from barrier method	CHC can be started at any time. At any other time if it is reasonably certain is not pregnant.	None if up to and including day 5. If starting CHC after day 5, required for 7 days 9 days for Qlaira®

****Please note if changing from one CHC to an alternative CHC and have had a 7 day hormone free interval, additional precautions and need for EC maybe required****

Current Prescribing Guidelines

Yasmin®:

Yasmin®/Lucette® contains 30 micrograms ethinylestradiol plus 3 micrograms drospirenone (an anti-mineralocorticoid gestogen).

Please note: Yasmin®/Lucette® is non formulary in NHS GGC and non-formulary systems may apply. It does not have SMC approval.

Indications:

This should be offered only as third line oral contraceptive where there have been side effects related to fluid retention, mood change, acne or true weight gain related to oral contraception and other methods of contraception have been discussed. Careful documentation of the side effects should be made.

Clients should have tried at least two COCs with different gestogens.

Yasmin/Lucette® is not stocked or supplied from Sandyford. Clients may opt to discuss prescription from GP

Co-cyprindiol

Dianette®, Clairette®, Acnecin® and Cicalfem® contains 35 micrograms EE plus 2 micrograms Cyproterone acetate and are not licensed as a COC.

Recent data confirms that **co-cyprindiol has a VTE risk which is greater than second generation CHCs, but is equivalent to that of third generation CHC.**

Indications:

In the UK the CSM advises:

- **Co-cyprindiol is not indicated solely as a contraceptive;** it is a treatment option for those with severe acne, which has not responded to oral antibiotics, or for moderately severe hirsutism.
- It should be withdrawn 3 – 4 months after the treated conditions has resolved or if there is no improvement in symptoms.
- If a women wishes to continue with a combined oral contraceptive pill an alternative preparation should be offered with a progestogen with low androgenic side effects e.g. Gestodene or Desogestrel.
- There are however a number of users whose skin control deteriorates significantly on withdrawal of Co-cyprindiol and they should be counselled on an individual basis with regard to the risks and benefits of this preparation for them as it may be that it is on balance appropriate for them to continue with Co-cyprindiol, and a 12 month supply can be offered if appropriate.

Evra® / NuvaRing®

- If availability of hormone is likely to be improved by the transdermal / transmucosal route of absorption as opposed to the use of an oral preparation (inability to take tablets, bowel disease).
- Where a woman chooses and is suitable for combined hormonal contraception, and continuation of the method would be improved by the transdermal / transmucosal system of a once weekly patch change or four weekly ring change (including one week ring free).
- Cost effectiveness should also be considered with the reduction in price per cycle.

CoSRH Advice incorrect use COC

Guidance on actions after incorrect use of combined oral contraception (monophasic ethinylestradiol COC without placebo pills only)

Late restarting after HFI



1 missed pill (48 to <72hours since last pill in current pack was taken)




* if consistent, correct use earlier in week 1 and the 7 days prior to the HFI



**if consistent, correct use in the previous 7 days

2 or more missed pills (≥72 hours since last pill in current pack was taken)



**if consistent, correct use in the previous 7 days




³ Overcautious, but a back-up in case of subsequent incorrect use


Abbreviations: COC, combined oral contraception; EC, emergency contraception; HFI, hormone-free interval; UPSI, unprotected sexual intercourse

Guidance on actions after incorrect use of the combined vaginal ring


Late restarting ring after scheduled HFI




Unscheduled ring removal for <48 hours



Unscheduled ring removal for ≥48 hours



Accidental continued use of the same ring beyond 3 weeks




Guidance on actions after incorrect use of the combined transdermal patch

Late restarting patch after scheduled HFI



Unscheduled patch detachment for <48 hours or continued use of same patch for up to 48 additional hours




* if correct use earlier in week 1 and the 7 days prior to the HFI



** if correct use in the previous 7 days

Unscheduled patch detachment for ≥48 hours or continued use of the same patch for ≥48 additional hours



Appendix

Definition of UK MEC Categories

UKMEC	DEFINITION OF CATEGORY
CATEGORY 1	A condition for which there is no restriction for the use of the contraceptive method.
CATEGORY 2	A condition where the advantages of using the method generally outweigh the theoretical or proven risks.
CATEGORY 3	A condition where the theoretical or proven risks usually outweigh the advantages of using the method.
CATEGORY 4	A condition which represents an unacceptable health risk if the contraceptive method is used.

Combined Hormonal Contraception Regimens

Type of regimen	Period of CHC use	HFI
Standard use	21 days (21 active pills or 1 ring, or 3 patches)	7 days
Tailored use		
Shortened hormone-free interval (HFI)	21 days (21 active pills or 1 ring, or 3 patches)	4 days
Extended use (tricycling)	9 weeks (3 x 21 active pills or 3 rings, or 9 patches used consecutively)	4 or 7 days
Flexible extended use	Continuous use (≥ 21 days) of active pills, patches or rings until breakthrough bleeding occurs for 3–4 days	4 days
Continuous use	Continuous use of active pills, patches or rings	None

Key messages for women considering use of tailored CHC regimens

- ▶ The evidence from studies is that combined hormonal contraception (CHC) is as safe and at least as effective for contraception if it is taken as an extended or continuous regimen as it is when it is taken in a traditional 21/7 cycle.
- ▶ A woman who is using CHC does not need to have a monthly withdrawal bleed to be healthy.
- ▶ There is no build-up of menstrual blood inside a woman who uses CHC for an extended time without a break; extended CHC use keeps the lining of the womb thin.
- ▶ Withdrawal bleeds during cyclical use of CHC have been reported by women who are pregnant; women should not consider monthly bleeds on CHC to be reassurance that they are not pregnant.
- ▶ By using extended or continuous CHC the frequency of withdrawal bleeds and associated symptoms (e.g. headache, mood change) is reduced; this could be useful for women who have heavy or painful bleeding or problematic symptoms associated with the hormone-free interval (HFI).
- ▶ The ovaries start to become active during the traditional 7-day HFI. Fewer and/or shorter breaks in CHC use could mean that the risk of pregnancy could *theoretically* be lower with extended or continuous regimens than if a 7-day break is taken every month.
- ▶ There can be irregular bleeding or spotting in the first few months of CHC use, particularly with extended or continuous regimens; this does not usually mean that there is any medical problem and it generally improves with time.
- ▶ The evidence from studies is that using extended or continuous regimens of CHC does not affect the return of a woman's fertility when she stops CHC.

References:

- [CoSRH UK Medical Eligibility Criteria for contraceptive use](#) (UKMEC2016) (accessed Dec 2025)
- CoSRH [Drug Interactions with Hormonal Contraception](#). (2017, reviewed 2019) (accessed Dec 2025)
- [CoSRH Guideline Emergency Contraception](#). March 2017, amended Dec 2020 (accessed Dec 2025)
- CoSRH [Combined hormonal contraception January 2019, updated July 2019 and Oct](#) (accessed Dec 2025)
- [CoSRH GLP1 Agonists 2025](#) (accessed Nov 25)

Patient Information Leaflets
www.nhs.inform